administer an extensive study of wine types from around the world | utilise extensive study of wine types from around the world | apply extensive study of wine types from around the world | applying extensive study of wine types from around the world

Type of study performed on tumor specimen

case comparison study | case compeer study | case reference study | case referent study | case-control study

prices of wood products studying | study wood product prices | study prices of wood products | studying prices of wood products

directed private study | directed self study | guided private study | guided self-study | tutorial

bioavailability study | bioequivalence study | comparative bioavailability study | relative bioavailability study

apply the study of beer styles from around the world | implement extensive study of beer styles from around the world | administer extensive study of beer styles from around the world | apply extensive study of beer styles from around the world

type of study

A group of tyrosine related oculocutaneous albinism (OCA1) that includes OCA1A, OCA1B, type 1 minimal pigment oculocutaneous albinism (OCA1-MP) and type 1 temperature sensitive oculocutaneous albinism (OCA1-TS). The phenotypic spectrum seen in OCA1 i

Disease that is characterized by massive enteric protein loss, secretory diarrhea and intolerance to enteral feeds during the first few weeks of life. It has been described in three male infants. Histochemical studies revealed a complete absence of e

310. Considers that the concept/idea of Sustainability Impact Assessment Studies is to be applied for all types of financial support, not only in the Commission expenditure, but in all Union institutions, bodies and agencies; considers that expenditure which does comply with an impact assessment study/analysis should not be permitted and allowed;

(Return tabled) Question No. 104 Hon. Wayne Easter: With regard to imprisonment for life: (a) what offences in the Criminal Code allow for imprisonment for life; (b) how many individuals have been charged with an offence carrying with it a sentence of imprisonment for life, for each of the last ten years, broken down by province and offence; (c) for the individuals charged in (b), how many were convicted; (d) for the individuals in (c), how many received a sentence of life imprisonment; (e) how many individuals in Canada are serving a sentence of “imprisonment for life” and broken down by province and offence, (i) in what year were they sentenced, (ii) how many have been designated as dangerous offenders, (iii) of those designated in (i ...[+++]i), how many have received parole in the last 20 years, broken down by year, (iv) of those designated in (iii), how many have reoffended while on parole; (f) how many prisoners serving a sentence of imprisonment for life applied for parole and how many of them received parole, broken down by year, for the last 20 years; (g) what is the percentage of prisoners sentenced to life whose parole is approved, broken down by year, for the last 25 years, (i) of those sentenced to life, what type of parole was granted, (ii) of the breakdown in (i), how many committed an offence, (iii) what is the recidivism rate of those sentenced for life who are granted parole; (h) what is the percentage of prisoners not sentenced to life whose parole was approved, broken down by year, for the last 25 years, (i) of those not sentenced to life, what type of parole was granted, (ii) of the breakdown in (i), how many committed an offence, (iii) what is the recidivism rate of those not sentenced for life who are granted parole; (i) is there evidence to demonstrate that offenders sentenced to life and granted parole are more likely to reoffend while on parole than offenders not sentenced to life who are granted parole, (i) what evidence has the government ...

(Return tabled) Question No. 121 Mr. Ted Hsu: With regard to the implementation of the Foreign Account Tax Compliance Act (FATCA): (a) what steps has Canada undertaken to complete an Inter-Governmental Agreement (IGA) with the United States; (b) with what type of legal instrument will the government enact a FATCA implementation agreement; (c) will the government bring an IGA before Parliament and, if so, in what form; (d) what steps are in place to ensure parliamentary review of an IGA; (e) what studies have been undertaken as to ...[+++]whether an IGA can be implemented as an interpretation of the existing double tax treaty; (f) in what ways will the government involve Parliament in any process to amend interpretation of the double taxation treaty; (g) who is involved in the process indicated in (a); (h) by what criteria is the government evaluating any proposed IGA with the US; (i) who established the criteria in (h), (i) on what date, (ii) under what authority; (j) is a draft IGA currently being negotiated, and if so, what is the status of said negotiations; (k) when will the draft IGA be made public; (l) will the public be consulted for input on any agreement, and if so, by what means; (m) with which specific individuals and groups did the Minister of National Revenue consult regarding FATCA, and on what dates; (n) with which specific individuals and groups did the Minister of National Revenue consult regarding any IGA, and on what dates; (o) with which specific individuals and groups did the Minister of Finance consult regarding FATCA, and on what dates; (p) with which specific individuals and groups did the Minister of Finance consult regarding any IGA, and on what dates; (q) what studies and analyses has the Department of Finance undertaken with respect to FATCA; (r) what studies and analyses has the Department of National Revenue undertaken with respect to FATCA; (s) what analyses and studies have been undertaken as to whether the proposed FATCA re ...

Question No. 53 Ms. Kirsty Duncan: With respect to the chronic cerebrospinal venous insufficiency (CCSVI) clinical trial being undertaken by Dr. Traboulse: (a) what milestones are reportable to the government, (i) on what date(s) is reporting expected to occur, (ii) how will this information be communicated to patients, the medical community, and the general public; (b) on what date did each of the trial sites pass ethical review; (c) on what date did recruitment of patients begin for each of the trial sites; (d) how many patients with multiple sclerosis (MS) are being recruited for each site, and how is consistency in diagnosis and treatment being ensured across sites; (e) who is performing the diagnoses for CCSVI for each site, (i) ho ...[+++]w is the diagnosis being performed, including, but not limited to, ultrasound and venogram, (ii) how many diagnoses has each person undertaking the diagnosis at each site performed prior to the study, and by whom was each person trained; (f) who is performing the procedures for each site, (i) how is the procedure being performed, including, but not limited to, anesthetic, balloon size, (ii) how many procedures has each person undertaking the procedure at each site performed prior to the study, and by whom was each person trained; (g) what are the selection criteria for the trial, including, but not limited to, type of MS, Expanded Disability Status Scale (EDSS) score, venous abnormality/malformed valve/stenosis, mobility, (i) how do these criteria compare with the international literature, (ii) with how many international studies to date will the selection criteria be analytically comparable; (h) if both progressive and relapsing-remitting forms of MS are to be examined in the trial, how will statistical significance be ensured given that 50 of 100 patients will undergo a “sham” procedure, 25 patients will have a progressive form of the disease, and 25 will have a relapsing-remitting form of the disease, and will people with bo ...